The measurement of newer biomarkers such as cystatin C, kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) to diagnose AKI is unavailable in developing countries, and even tests that are routine in higher income countries, such as serum creatinine (sCr), are often unavailable [14, 15]. Here, LCN2 is linked to acute kidney injury.